Currently, Continuous intraperitoneal insulin infusion (CIPII) is used as a last‐resort treatment option for selected patients with type 1 diabetes mellitus (T1DM) who fail to reach glycaemic control despite intensive subcutaneous (SC) insulin therapy. The gene discussed is INS; the disease is type 1 diabetes mellitus.